Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mbIL21-expanded donor-derived natural killer cells
- Development stage
- Unknown
- Lead developer
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
mbIL21-expanded donor-derived natural killer cells is an adoptive cell therapy developed by the Federal Research Institute of Pediatric Hematology, Oncology and Immunology. The therapy involves the ex vivo expansion of natural killer (NK) cells obtained from a donor (haploidentical or matched-related) using a feeder system expressing membrane-bound interleukin-21 (mbIL21). This expansion process is designed to significantly increase the number and cytotoxic potential of the NK cells. The cells are administered to pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemias, including acute myeloid leukemia (AML), acute T-lymphoblastic leukemia (T-ALL), and mixed phenotype acute leukemia (MPAL), in conjunction with hematopoietic stem cell transplantation (HSCT). The goal of the therapy is to provide a potent graft-versus-leukemia effect to eradicate residual leukemic cells and prevent disease relapse post-transplant.
- Other names
- Donor-derived Natural Killer CellmbIL21 ex vivo-expanded donor-derived NK-cell infusionsmbIL-21 ex vivo-expanded donor-derived NK-cell infusionsmbIL 21 ex vivo-expanded donor-derived NK-cell infusions
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL21R (Interleukin-21 receptor)Killer cell immunoglobulin-like receptor (KIR) family / Human leukocyte antigen (HLA) class I ligands
Beyond the preview
Go deeper on mbIL21-expanded donor-derived natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mbIL21-expanded donor-derived natural killer cells.